UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/829,505	04/22/2004	Shan X. Wang	STAN-571	6970
Stanford University Office of Technology Licensing Bozicevic, Field & Francis LLP			EXAMINER	
			DO, PENSEE T	
1900 University Avenue Suite 200			ART UNIT	PAPER NUMBER
East Palo Alto, CA 94303			1641	
			MAIL DATE	DELIVERY MODE
			07/20/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/829,505	WANG ET AL.			
Office Action Summary	Examiner	Art Unit			
	Pensee T. Do	1641			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w.  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	l. lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>27 Mar</u> This action is <b>FINAL</b> . 2b) ☑ This      Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 1-17 and 19-47 is/are pending in the a 4a) Of the above claim(s) 20-47 is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1-17 and 19 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-17 and 19-47 are subject to restriction  Application Papers  9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the objection to the objection is objected.	on from consideration.  on and/or election requirement.  r. epted or b) □ objected to by the E				
Replacement drawing sheet(s) including the correcti	÷.,	, ,			
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date 11/09/07.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	te			

Application/Control Number: 10/829,505 Page 2

Art Unit: 1641

#### **DETAILED ACTION**

#### **DETAILED ACTION**

### **Priority**

This application <u>10829505</u>, with PG Pub. No. <u>20050100930</u> filed 04/22/2004, claims Priority from Provisional Application 60519378, filed 11/12/2003.

Child Data: Application <u>11655561</u>, filed on 01/18/2007, now abandoned is a continuation in part of <u>10829505</u>, filed on 04/22/2004. Application <u>11804583</u>, filed on 05/17/2007 is a division of <u>10829505</u>, filed on 04/22/2004.

Application <u>11938187</u>, filed on 11/09/2007 is a division of <u>10829505</u>, filed on 04/22/2004

# Amendment Entry & Claims Status

The amendment filed on March 27, 2008 has been acknowledged and entered.

Claims 1-17, 19 are being examined.

Claims 20-47 are withdrawn.

## Withdrawn Rejection(s)

Rejection under 112, 2nd paragraph in the previous office action is withdrawn.

Rejections under 102 and 103 in the previous office action are withdrawn herein.

#### Claimed Invention

1. (Currently Amended) A method of detecting a molecule of interest complex, the method comprising:

providing a first molecule bonded to at least one magnetizable nanoparticle; providing a second molecule bonded to a substrate;

Art Unit: 1641

contacting the first molecule to the second molecule under conditions suitable for selective binding of the first molecule to the second molecule to form a complex; and

detecting the complex, wherein said detecting comprises applying a DC bias field and an AC tickling field.

# **New Grounds of Rejection**

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-8, 10, 11, 17, 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fox (WO 01/14591, published March 1, 2001) in view of Dames (US 6,323,770).

Fox teaches a method of detecting a molecule of interest, the method comprises providing a first molecule bonded to a magnetizable nanoparticle; providing a second molecule bonded to a substrate; contacting the first molecule with the second molecule to promote binding between the two molecules to form a complex; detecting the complex. (see pg. 20, lines 15-18; pg. 6, lines 15-20). For claims 2-8, Fox teaches that the target molecule/specific binding molecule (first molecule or second molecule respectively) are among proteins (antigens/antibodies), polypeptides, nucleic acids (see

pg. 11, lines 14-15; pg. 20, lines 14-15; pg. 21, lines 6-7). For claims 10-11, Fox teaches that the magnetic particles are ferromagnetic, ferrimagnetic, paramagnetic or superparamagnetic. (see pg. 8, lines 20-23). Fox teaches using a sensitive giant magnetoresistive ratio sensor (GMR) to detect the complex. The GMR sensor advantageously includes biasing magnets for producing an applied biasing magnetic field. The input voltage and the output sensor are routed to an operational amplifier and the output signal (net signal) is measured. This output signal will vary with the intensity of the an externally applied magnetic field. (for claims 17 and 19). (see pg. 13, line 25-pg. 14, line 10).

However, Fox fails to teach said detecting comprises applying a DC bias field and an AC tickling field.

Dames teaches using a DC current and AC current to detect a magnetic tag. The DC current is applied to the magnetic tag and an AC current is then applied. This AC current is caused to flow in opposite direction of the DC current. (see col. 5, lines 40-51; col. 6, lines 37-65).

It would have been obvious to one of ordinary skills in the art to apply the concept of using DC current and AC current (low frequency AC tickling field) to detect magnetic response of a magnetic tag as taught by Dames to the method of Fox to detect predetermined region of a magnetic marker or particles in assay.

Claims 1-8, 10, 11, 14-17, 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Coehoorn et al. (WO 03/054523, published July 3, 2003) in view of Dames (US 6,323,770).

Coehoorn teaches a method of magnetic detection comprising providing biological molecules on a substrate of a magnetoresistive device; adding magnetic nanoparticles conjugated with binding molecules specific for the biological molecules on the substrate of the magnetoresistive device so that the biological molecules on the substrate and the nanoparticles form a complex; detecting such complex. (see abstract; pg. 5, lines 18-30). For claims 2-8, Coehoorn teaches the molecules are DNA, RNA, proteins (antigens or antibodies), or peptides, etc. (see pg. 8, lines 3-20). For claims 10 and 11, Coehoorn teaches that the magnetic nanoparticles are superparamagnetic. For claims 14 and 15, Coehoorn teaches that the magnetic nanoparticles diameter range between and 250 nm, preferably between 3 and 100 nm, or 10 and 60 nm. (see pg. 5, lines 28-36). For claim 16, Coehoorn teaches using a spin-valve substrate. (see table on pg. 23). For claims 17 and 19, Coehoorn teaches an external magnetic field is applied and a net signal generated by the magnetic field in the plane of the GMR elements is detected. (see pg. 11, lines 17-19; pg. 11, lines 28-33).

However, Coehoorn fails to teach said detecting comprises applying a DC bias field and an AC tickling field.

Dames teaches using a DC current and AC current to detect a magnetic tag. The DC current is applied to the magnetic tag and an AC current is then applied. This AC

current is caused to flow in opposite direction of the DC current. (see col. 5, lines 40-51; col. 6, lines 37-65).

It would have been obvious to one of ordinary skills in the art to apply the concept of using DC current and AC current (low frequency AC tickling field) to detect magnetic response of a magnetic tag as taught by Dames to the method of Coehoorn to detect predetermined region of a magnetic marker or particles in assay.

Claims 1, 2-8, 10, 11, 17 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baselt (US 5,981,297, Nov. 9, 1999) in view of Dames (US 6,323,770).

Baselt teaches a method for detecting target molecules. The method comprises providing a recognition molecules bound to a surface of a magnetic field sensor; adding target molecules bound to magnetic particles; exposing the magnetic particles bound target molecules to the surface of the magnetic field sensor bound recognition molecules so that the molecules form a complex; detecting such complex. (see col. 3, lines 39-59). For claims 2-8, Baselt teaches that the recognition molecules or the target molecules are peptides, antibodies, DNA or RNA, proteins, etc. (see col. 4, lines 3-7). For claims 10 and 11, Baselt teaches that the magnetic particles are superparamagnetic (see col. 3, lines 60-65). For claim 17, Baselt teaches applying an external magnetic field to detect the complex. (see col. 7, lines 25-30). For claim 19, Baselt teaches

Art Unit: 1641

detecting a net signal or resistance change in the magnetoresistive element. (see col. 8, lines 8-24).

However, Baselt fails to teach said detecting comprises applying a DC bias field and an AC tickling field.

Dames teaches using a DC current and AC current to detect a magnetic tag. The DC current is applied to the magnetic tag and an AC current is then applied. This AC current is caused to flow in opposite direction of the DC current. (see col. 5, lines 40-51; col. 6, lines 37-65).

It would have been obvious to one of ordinary skills in the art to apply the concept of using DC current and AC current (low frequency AC tickling field) to detect magnetic response of a magnetic tag as taught by Dames to the method of Baselt to detect predetermined region of a magnetic marker or particles in assay.

Claims 1-8, 10, 11, 14, 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Terstappen et al. (US 6,623,983, September 23, 2003) in view of Dames (US 6,323,770).

Terstappen teaches a method for immobilizing magnetically labeled particulate entities on a collection surface via binding between specific binding pair members. The method comprises providing one member of a specific binding pair bound to the collection surface and the other member bound to magnetic nanoparticles; exposing the magnetic nanoparticles bound binding member to the collection surface to form a complex between the binding members; detecting said complex. (see col. 6, lines 18-

50;col. 12, lines 53-57). For claims 2-8, Terstappen teaches the binding members are proteins (antibodies, antigens, peptides,) or RNA or DNA. (see col. 8, lines 50-55; col. 9, lines 20-25; col. 10, lines 29-30). For claims 10 and 11, Terstappen teaches that the magnetic nanoparticles are superparamagnetic. (see col. 2, lines 42-44). For claims 14 and 15, Terstappen teaches the diameter of the magnetic nanoparticles range from 20-25 nm (see col. 2, line 53) or less than 200 nm. (see col. 9,line 64).

However, Terstappen fails to teach said detecting comprises applying a DC bias field and an AC tickling field.

Dames teaches using a DC current and AC current to detect a magnetic tag. The DC current is applied to the magnetic tag and an AC current is then applied. This AC current is caused to flow in opposite direction of the DC current. (see col. 5, lines 40-51; col. 6, lines 37-65).

It would have been obvious to one of ordinary skills in the art to apply the concept of using DC current and AC current (low frequency AC tickling field) to detect magnetic response of a magnetic tag as taught by Dames to the method of Terstappen to detect predetermined region of a magnetic marker or particles in assay.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 9, 12 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Fox, or Baselt or Coehoorn in view of Dames as applied to claim 1, and further in view of Berning et al. (PGPub US 2005/0025969).

Fox, Baselt, Coehoorn and Dames have been discussed above.

However, they fail to teach that the first molecule is covalently bonded to at least one magnetizable nanoparticle by a gold-thiol linkage, and the nanoparticle comprises a noble metal surface layer such as a gold surface layer.

Berning teaches nanoparticles coated with a layer of gold including a magnetic nanoparticle central core, and a coating of gold completely encapsulating the magnetic nanoparticle central core. The composite further comprises thiol-bound functional group-containing spacer groups thereon the gold-coated magnetic nanoparticles. (see [0009]. The gold-coated magnetic nanoparticles are further coupled to recognition group such as proteins, peptides, nucleic acids, (see [0014]. The size of the magnetic nanoparticles range from 10 nm to 250 nm. (see [0011]).

It would have been obvious to one of ordinary skills in the art to use the magnetic nanoparticles coated with a gold surface layer and thiol group as taught by Berning the method of Fox, Baselt or Coehoorn because such gold-coated magnetic nanoparticles of Berning would prevent direct bio-contact to the magnetic material thus improving biocompatibility. A gold surface also allows good coupling through chemical attachment of binding agents or recognition agents such as peptides, proteins or nucleic acids. (see Berning [0010]).

Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over Fox or Baselt in view of Ferreira et al. (Journal of Applied Physics Vol. 93, No. 10, 15 May 2003, pp. 7281-7286 submitted by Applicants).

Fox and Baselt have been discussed above.

However, they fail to teach the substrate comprises a high sensitivity spin valve or a magnetic tunnel junction detector array.

Ferreira teaches using arrays spin valve sensors to detect magnetically labeled biomolecules. (See abstract, pg. 7282, col. 1, A).

Since Fox and Baselt teaches using GMR elements, it would have been obvious to one of ordinary skills in the art to use the spin valve element of GMR as taught by Ferreira to detect magnetic beads since spin valve-type GMR is a highly sensitive magnetic sensor element which exhibits a high-signal to noise ratio of output and stable operation.

#### Declaration

The declaration filed on September 19, 2007 has been acknowledged and considered. It is found persuasive and therefore the Li reference is withdrawn from the rejections in the previous office action.

## Response to Arguments

Applicant's arguments with respect to claims 1-17 and 19 have been considered but are most in view of the new ground(s) of rejection.

Art Unit: 1641

Applicants filed a declaration submitting that the co-authors in the Li reference did not make any contribution to the present claimed invention and that the work in Li reference is applicants' own work.

Therefore, rejections in the previous office action for claim 18 is withdrawn.

Applicants also incorporated the limitation of claim 18 into claim 1 and cancelled claim 1. The newly cited Dames patent remedy the deficiency of claim 18 (which is now in claim 1).

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pensee T. Do whose telephone number is 571-272-0819. The examiner can normally be reached on Monday-Friday, 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Shibuya can be reached on 571-272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/829,505 Page 12

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Pensee T. Do/ Examiner, Art Unit 1641

/Mark L. Shibuya/ Supervisory Patent Examiner, Art Unit 1641